File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children
  • Basic View
  • Metadata View
  • XML View
TitleA comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children
 
AuthorsLau, YL6
Vessey, SJR4
Chan, ISF4
Lee, TL6
Huang, LM5
Lee, CY5
Lin, TY1
Lee, BW7
Kwan, K3
Kasim, SM2
Chan, CY4
Kaplan, KM4
Distefano, DJ4
Harmon, AL4
Golie, A4
Hartzel, J4
Xu, J4
Li, S4
Matthews, H4
Sadoff, JC4
Shaw, A4
 
Issue Date2002
 
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
CitationVaccine, 2002, v. 20 n. 23-24, p. 2942-2949 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0264-410X(02)00245-1
 
AbstractThis study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. © 2002 Elsevier Science Ltd. All rights reserved.
 
ISSN0264-410X
2012 Impact Factor: 3.492
2012 SCImago Journal Rankings: 1.360
 
DOIhttp://dx.doi.org/10.1016/S0264-410X(02)00245-1
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLau, YL
 
dc.contributor.authorVessey, SJR
 
dc.contributor.authorChan, ISF
 
dc.contributor.authorLee, TL
 
dc.contributor.authorHuang, LM
 
dc.contributor.authorLee, CY
 
dc.contributor.authorLin, TY
 
dc.contributor.authorLee, BW
 
dc.contributor.authorKwan, K
 
dc.contributor.authorKasim, SM
 
dc.contributor.authorChan, CY
 
dc.contributor.authorKaplan, KM
 
dc.contributor.authorDistefano, DJ
 
dc.contributor.authorHarmon, AL
 
dc.contributor.authorGolie, A
 
dc.contributor.authorHartzel, J
 
dc.contributor.authorXu, J
 
dc.contributor.authorLi, S
 
dc.contributor.authorMatthews, H
 
dc.contributor.authorSadoff, JC
 
dc.contributor.authorShaw, A
 
dc.date.accessioned2012-10-30T06:31:58Z
 
dc.date.available2012-10-30T06:31:58Z
 
dc.date.issued2002
 
dc.description.abstractThis study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. © 2002 Elsevier Science Ltd. All rights reserved.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationVaccine, 2002, v. 20 n. 23-24, p. 2942-2949 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0264-410X(02)00245-1
 
dc.identifier.doihttp://dx.doi.org/10.1016/S0264-410X(02)00245-1
 
dc.identifier.epage2949
 
dc.identifier.issn0264-410X
2012 Impact Factor: 3.492
2012 SCImago Journal Rankings: 1.360
 
dc.identifier.issue23-24
 
dc.identifier.pmid12126906
 
dc.identifier.scopuseid_2-s2.0-0037178307
 
dc.identifier.spage2942
 
dc.identifier.urihttp://hdl.handle.net/10722/173455
 
dc.identifier.volume20
 
dc.languageeng
 
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVaccine
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAntibodies, Viral - Blood
 
dc.subject.meshChickenpox Vaccine - Adverse Effects - Immunology
 
dc.subject.meshDouble-Blind Method
 
dc.subject.meshDrug Tolerance
 
dc.subject.meshEnzyme-Linked Immunosorbent Assay
 
dc.subject.meshFemale
 
dc.subject.meshHerpesvirus 3, Human - Immunology
 
dc.subject.meshHumans
 
dc.subject.meshInfant
 
dc.subject.meshMale
 
dc.subject.meshSafety
 
dc.subject.meshVaccines, Attenuated - Adverse Effects - Immunology
 
dc.titleA comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lau, YL</contributor.author>
<contributor.author>Vessey, SJR</contributor.author>
<contributor.author>Chan, ISF</contributor.author>
<contributor.author>Lee, TL</contributor.author>
<contributor.author>Huang, LM</contributor.author>
<contributor.author>Lee, CY</contributor.author>
<contributor.author>Lin, TY</contributor.author>
<contributor.author>Lee, BW</contributor.author>
<contributor.author>Kwan, K</contributor.author>
<contributor.author>Kasim, SM</contributor.author>
<contributor.author>Chan, CY</contributor.author>
<contributor.author>Kaplan, KM</contributor.author>
<contributor.author>Distefano, DJ</contributor.author>
<contributor.author>Harmon, AL</contributor.author>
<contributor.author>Golie, A</contributor.author>
<contributor.author>Hartzel, J</contributor.author>
<contributor.author>Xu, J</contributor.author>
<contributor.author>Li, S</contributor.author>
<contributor.author>Matthews, H</contributor.author>
<contributor.author>Sadoff, JC</contributor.author>
<contributor.author>Shaw, A</contributor.author>
<date.accessioned>2012-10-30T06:31:58Z</date.accessioned>
<date.available>2012-10-30T06:31:58Z</date.available>
<date.issued>2002</date.issued>
<identifier.citation>Vaccine, 2002, v. 20 n. 23-24, p. 2942-2949</identifier.citation>
<identifier.issn>0264-410X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/173455</identifier.uri>
<description.abstract>This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX&#8482; [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (&#8764;50,000 plaque forming units (PFU), Group A or &#8764;16,000PFU, Group B) or 1 dose of VARILRIX&#8482;, (&#8764;40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer &#8805;5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. &#169; 2002 Elsevier Science Ltd. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/vaccine</publisher>
<relation.ispartof>Vaccine</relation.ispartof>
<subject.mesh>Antibodies, Viral - Blood</subject.mesh>
<subject.mesh>Chickenpox Vaccine - Adverse Effects - Immunology</subject.mesh>
<subject.mesh>Double-Blind Method</subject.mesh>
<subject.mesh>Drug Tolerance</subject.mesh>
<subject.mesh>Enzyme-Linked Immunosorbent Assay</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Herpesvirus 3, Human - Immunology</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Infant</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Safety</subject.mesh>
<subject.mesh>Vaccines, Attenuated - Adverse Effects - Immunology</subject.mesh>
<title>A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX&#8482; in healthy children</title>
<type>Conference_Paper</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/S0264-410X(02)00245-1</identifier.doi>
<identifier.pmid>12126906</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0037178307</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0037178307&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>20</identifier.volume>
<identifier.issue>23-24</identifier.issue>
<identifier.spage>2942</identifier.spage>
<identifier.epage>2949</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. Chang Gung Meorial Hospital
  2. Institut Pediatrik
  3. Klinik Kanak Kanak Kwan
  4. Merck &amp; Co.
  5. National Taiwan University Hospital
  6. Queen Mary Hospital Hong Kong
  7. National University Hospital, Singapore